In addition, neither the tissue expression of PD-L1 nor the mutational tumor load was able to discriminate a subgroup associated with improved efficacy of first- and second-line immunotherapies in any clinical trial in SCLC [4,5,6,7,8,9]. This evidence concerns the gene CD274 and small cell lung carcinoma.